Atopic dermatitis. A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin, with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested b
Conditions
Interventions
Intervention 1: Intervention group: Two 15 g sachets of freeze-dried whey powder into a glass containing 200 ml of water with two 500 mg capsules containing spray dried extract of dodder twice a day
Treatment - Drugs
Placebo
Intervention group: Two 15 g sachets of freeze-dried whey powder into a glass containing 200 ml of water with two 500 mg capsules containing spray dried extract of dodder twice a day for 15 days
Control group: Two 15 g sachets of corn starch into a glass containing 200 ml of water with two 500 mg capsules containing starch twice a day for 15 days
Sponsors
Vice chancellor for research, School of Traditional Medicine, Shahid Beheshti University of Medical
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Diagnosis of atopic dermatitis according to the criteria of Hanifin and Rajka; Poor response to conventional treatment (topical steroids and oral antihistamines); No active exudation or infection; Patients aged 18 years or older; No pregnancy or lactation; Other systemic disease or dermatitis does not exist; Written informed consent of patient; Exclusion criteria: Secondary bacterial infection; Oral or intravenous steroid treatment, antibiotics, phototherapy or other immunosuppressive therapies (such as cyclosporine or azathioprine); Drug intolerance; Diseases that can affect drug absorption; Inability to participate in follow-up process
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Skin hydration level. Timepoint: Before the intervention, immediately after the end of the intervention (post-treatment assessment) and two weeks after the end of intervention (follow-up). Method of measurement: By using the multi skin test center MC1000 device with the software complete skin investigation.;Skin pigmentation level. Timepoint: Before the intervention, immediately after the end of the intervention (post-treatment assessment) and two weeks after the end of intervention (follow-up). Method of measurement: By using the multi skin test center MC1000 device with the software complete skin investigation.;Skin elasticity level. Timepoint: Before the intervention, immediately after the end of the intervention (post-treatment assessment) and two weeks after the end of intervention (follow-up). Method of measurement: By using the multi skin test center MC1000 device with the software complete skin investigation.;Skin pH level. Timepoint: Before the intervention, immediately after the end of the intervention (post-treatment assessment) and two weeks after the end of intervention (follow-up). Method of measurement: By using the multi skin test center MC1000 device with the software complete skin investigation.;Skin sebum level. Timepoint: Before the intervention, immediately after the end of the intervention (post-treatment assessment) and two weeks after the end of intervention (follow-up). Method of measurement: By using the multi skin test center MC1000 device with the software complete skin investigation.;Skin lesions. Timepoint: Before the intervention, immediately after the end of the intervention (post-treatment assessment) and two weeks after the end of intervention (follow-up). Method of measurement: By using the visioscope PC 35 skin camera. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehrzad Mehrbani
School of Traditional Medicine, Shahid Beheshti University of Medical Sciences
Outcome results
None listed